Abstract: Bone morphogenetic proteins (BMPs) are growth and differentiation factors involved during development in morphogenesis, organogenesis and later mainly in regeneration processes, in particular in bone where they are responsible for osteoinduction. For more than a decade, recombinant human (rh)BMP-2 has been used in the clinic for lumbar spinal fusion at non-physiological high dosages that appear to be causative for side effects, like male sterility. A possible strategy to reduce the effective amount of rhBMP-2 in the clinic is the co-delivery with an enhancer of BMPs' activity. In an earlier study, we showed that N-methylpyrrolidone (NMP) enhances BMP activity in vitro and in vivo. Here we report on the development of a slow and sustained double delivery of rhBMP-2 and NMP via an in situ forming implant based on poly(lactide-co-glycolide). The results showed that the release of NMP can be adjusted by varying the lactide/glycolide ratio and the polymer's molecular weight. The same applied to rhBMP-2, with release rates that could be sustained from two to three weeks. In the in vivo model of a critical size defect in the calvarial bone of rabbits, the implant containing 50 mol% lactide performed better than the one having 75 mol% lactide in terms of defect bridging and extent of bony regenerated area. In situ forming implants for the double delivery of the BMP enhancer NMP and rhBMP-2 appear to be promising delivery systems in bone regeneration. 
ABSTRACT
Bone morphogenetic proteins (BMPs) are growth and differentiation factors involved during development in morphogenesis, organogenesis and later mainly in regeneration processes, in particular in bone where they are responsible for osteoinduction. For more than a decade, recombinant human (rh)BMP-2 has been used in the clinic for lumbar spinal fusion at non-physiological high dosages that appear to be causative for side effects, like male sterility. A possible strategy to reduce the effective amount of rhBMP-2 in the clinic is the co-delivery with an enhancer of BMPs' activity. In an earlier study, we showed that N-methylpyrrolidone (NMP) enhances BMP activity in vitro and in vivo. Here we report on the development of a slow and sustained double delivery of rhBMP-2 and NMP via an in situ forming implant based on poly(lactide-co-glycolide). The results showed that the release of NMP can be adjusted by varying the lactide/glycolide ratio and the polymer's molecular weight. The same applied to rhBMP-2, with release rates that could be sustained from two to three weeks. In the in vivo model of a critical size defect in the calvarial bone of rabbits, the implant containing 50 mol% lactide performed better than the one having 75 mol% lactide in terms of defect bridging and extent of bony regenerated area. In situ forming implants for the double delivery of the BMP enhancer NMP and rhBMP-2 appear to be promising delivery systems in bone regeneration.
Introduction
Bone morphogenetic proteins (BMPs), members of the transforming growth factor-β superfamily of proteins, play an extremely important role in bone development and regeneration. The BMP-2 growth factor has been shown to maintain the osteoprogenitor cells, promote differentiation of osteoblasts, and is critical in bone healing [1] . Because of its major role in these processes, there have been significant efforts to deliver BMPs in an efficient manner to regenerate bone and commercial, FDA approved rhBMP products are available, e.g. OP-1™ (BMP-7, Olympus, Stryker) or BMP-2 (Infuse Bone Graft, Medtronic, Minneapolis). Numerous studies have explored synthetic polymers, naturally-derived materials, and calcium phosphates in formats including gels, injectable liquids, scaffolds, and particles [2] [3] [4] [5] [6] . Despite this body of work, high concentrations of rhBMPs are still needed for effective therapies. Doses on the order of milligrams are delivered to the patient, while physiologic concentrations are several orders of magnitude lower [7] . Various side effects, including ectopic bone formation, urogenital events, male sterility, osteolysis, and neck and throat swelling, can be caused or exacerbated by these high concentrations [8] . Additionally, since BMPs are produced recombinantly, they are very expensive treatments, especially when large doses are required.
Previously, our laboratory discovered the enhancing effects of N-methyl pyrrolidone (NMP) on rhBMP-2, which offers a means to lower the efficacious delivered BMP dose [9] . NMP has been demonstrated to both increase bone forming activities of osteoblasts and decrease bone resorption of osteoclasts [10] . An in vivo study using a rabbit calvarial defect model showed significantly higher bone regeneration with NMP alone by increasing the activity of the natural locally deposited autologous BMP [9] .
Furthermore, NMP is used as an injectable pharmaceutical excipient in FDA approved formulations and regarded as safe up to certain concentrations [11, 12] . Moreover, NMP is inexpensive and easily attainable; it is commonly used in various industries as a plasticizer and solvent.
To be able to take full advantage of the bone augmenting properties of NMP, it is important to retain NMP and deliver it over a sustained period of time. Previous studies have demonstrated the importance of slow delivery of rhBMP to obtain the best possible bone regeneration and provide the safest therapy [2, 13] . However, NMP, which is a small water and organic miscible molecule, is not easy to deliver slowly; NMP is cleared from the body within a few hours [14, 15] . Typically, conventional drug delivery strategies are not adapted to this type of molecule.
One drug delivery system that was developed to deliver a variety of different compounds utilizes NMP or another organic solvent to dissolve polyesters along with the drug substance. Upon immersion in an aqueous solution, a phase separation occurs in this so-called in situ forming implant (ISFI), and the water insoluble polymer precipitates to form a membrane surrounding a liquid interior [16] . Through diffusion of water into the ISFI and the efflux of the organic solvent, the drug is released over a sustained period of time with the release profile dependent on multiple factors, including the solvent, polymer properties, and composition. Four products based on Atrigel for alveolar ridge augmentation and other periodontal bone defects [17] [18] [19] , and an ISFI combined with tricalcium phosphate for non-weight bearing orthopedic applications [20] .The ISFI system possesses many benefits, including injectability, fast application, space filling without the need to cut material to size, and biocompatibility.
Furthermore it was shown to be bioadhesive to bone and teeth and to facilitate local delivery and limited pain [18, 21] .
Instead of using the ISFI system to deliver a classical drug, we have explored this technology to extend the release of NMP, which itself is a bioactive substance [9, 10] . By examining the dependence of the release profile on polymer properties, we have prolonged the release of NMP from hours to a few weeks. Moreover, this system has been expanded to also include BMP-2 for a greater enhancement of bone regeneration, rather than relying solely on the amount of growth factor that is naturally present. A calvarial defect model study in rabbits was performed to demonstrate the efficacy of this double delivery system.
Materials and Methods
All animal procedures were approved by the local authorities (Kantonales 
Implant Formation
Poly(DL-lactide) (PLA) and poly(DL-lactide-co-glycolide) PLGA were obtained from Boehringer Ingelheim (Ingelheim am Rhein, Germany). Polymers were dissolved overnight-shaking at 37°C to final 40 wt% in pure NMP (Sigma-Aldrich, St. Louis, MO) or a combination of NMP with water. Table 1 formic acid was used to analyse the samples, producing a UV peak that corresponded to the molecular weight of NMP. NMP concentration was quantified using the area under the curve of the peak of the UV signal at 210 nm compared to established NMP standards with a limit of quantification of 0.0625 mM NMP. There were at least three samples per group.
Degradation
The degradation study was performed similarly to the release study except that implants were removed at specified time points, blotted to remove excess buffer, and 
BMP-2 in Vitro Studies
Bone morphogenetic protein-2 produced in E. coli in our laboratory (detailed expression and purification procedures can be found in prior literature [22] Samples were heated at 37 °C for 10 min, NaOH was added to quench the reaction, and the optical density was read at 410 nm to measure alkaline phosphatase activity.
After initial testing of different conditions, the rhBMP-2 dissolved at 1 mg/mL in 1 mM HCl was added to the polymer and NMP by shaking at 37°C for 4-6 h for the release studies. As in the NMP release studies, polymers were 40 wt% in NMP plus BMP solution. The dissolved polymer with 10 µg rhBMP-2 was injected into a metal mesh basket and placed in 2 mL PBS with 6 M urea and maintained at 37°C on a turningwheel at 100 rpm. Additionally, rhBMP-2 at the same concentration in the PBS/urea buffer were used as controls. Individual samples and controls were removed at each timepoint (7, 14, 21 , and 28 days) and the supernatant was decanted and frozen at -20°C until analysis.
A Bio-Dot SF Microfiltration Apparatus (Bio-Rad, Hercules, CA) containing 48 slots with a nitrocellulose membrane was used to measure the concentration of released rhBMP-2 as described earlier [23] . 
Rabbit Implantation Studies
24 adult (12 month old) New Zealand white rabbits weighing between 3.5 and 4.2 kg were used in this study with six rabbits per group. A 15 mm circular full-thickness defect was created in the center of the calvaria using an electric burr. The bone was carefully removed, ensuring not to disturb the dura. A stepped titanium scaffold with an upper diameter of 17 mm, a lower diameter of 15 mm, and a total height of 3.8 mm was placed in the defect site. The titanium scaffold was produced by additive manufacturing using selective laser melting as described previously [24] . Rod thickness was 0.2 mm.
After fabrication, all samples were ultrasonically cleaned in a 4% Deconex kGy. Rabbits were sacrificed after 16 weeks and the calvaria were removed for histological processing as described [24] . Four different conditions were tested: titanium scaffold alone, titanium scaffold with RG502, titanium scaffold with RG502 containing 12 µg rhBMP-2 and titanium scaffold with RG752 containing 12 µg rhBMP-2. For the groups containing polymer, 200 µL of 40 wt% RG502 or RG752 dissolved in NMP with or without BMP-2 was deposited onto the center of the scaffold immediately before implanting.
Histology
The samples were first prepared with a sequential water substitution by ethanol process. Defatting took place in xylene. Next, the samples where infiltrated with methyl methacrylate (MMA, Aldrich Chemistry, Japan) and embedded by adding to 100 mL MMA, 3 g of di-benzoylperoxid and 10 mL plastoid N (Merck AG, Zug, Switzerland).
Polymerization was allowed to occur at 37°C in an incubator. Sections were prepared from the midst of the defects and ground to 25-50 µm. Thin-ground sections were stained with Coomassie brilliant blue and digital images taken to determine the bony regenerated area and the bony bridging via pixel measurement using ImageJ (Version
Bony regenerated area is defined as the fraction of the titanium scaffold where bone formation has occurred. It includes bone, bone marrow and the scaffold embedded in bone. Bone bridging was determined in the middle section. First, the areas with bone tissue were projected onto the x-axis. Next, the stretches of the x-axis where bone formation had occurred at any level were summed up as described earlier [25, 26] . Bone bridging is given in percentage of the defect width (15 mm) where bone formation has occurred.
Statistics
The primary analysis unit was the animal. For all parameters tested, treatment modalities were compared with a Kruskal-Wallis Test, followed by Mann-Whitney signed rank test for independent data (IBM SPSS v.19). Significance was set at P < 0.05. Data 
Results

NMP Release
Various polymers were tested to determine the effects of different factors on the release of NMP from the in situ forming implants. PLGA with different molecular weights but the same monomer ratio of 50% lactide and 50% glycolide were studied. The implants reproducibly filled the diameter of the mesh basket with a similar globular shape and a maximum 6% weight variation amongst implants. As shown in Figure 1a, higher polymer molecular weight led to faster release in the initial 24 h. RG502 released only 14.5% in the first 24 h, a low burst amount, whereas RG503 lost significantly more NMP, over 50% during this time period. However, the release rate of RG503 decreased after the initial 24 h and RG502's rate increased after a brief stagnation, causing the release from RG502 to surpass that of RG503 after 10 days (Figure 1b ). The crossover point occurred at approximately day 7. At days 7 and 10, the release from the two polymers was not statistically different. By day 14, the RG502 had released 100% of the NMP, whereas RG503 released only about 75%. RG503 then released all of the NMP by day 21.
In addition to comparing molecular weight, the ratio of the lactide and glycolide monomers was examined for its impact on NMP release. Figure 2a 
ISFI Degradation
The degradation profiles of the ISFIs with the two polymers containing 50% lactide, RG502 (14.5 kDa) and RG503 (42.6 kDa), were evaluated. Using GPC analysis, the molecular weight distribution of the ISFI was measured at multiple time points from 1 to 28 days. As shown in Figure 3 , the average M w of RG503 was initially much higher and the degradation rate steeper. However, by day 21, the RG503 ISFI M w was no longer different from RG502. 
BMP-2 Release
In order to include rhBMP-2 in the ISFI system, studies were performed to determine the effects of the NMP ISFI system on the activity on BMP-2 and of the BMP-2 on the NMP release. Since BMP-2 must be folded correctly to retain its activity and NMP could potentially disturb its secondary/tertiary structure, different process methods were evaluated. BMP-2 lyophilized and resuspended in 100% NMP resulted in a complete loss of activity, as measured by an alkaline phosphatase assay.
Furthermore, rhBMP-2 was no longer active when directly diluted in mixtures of NMP and acetic acid, even in 10% acetic acid/90% NMP (w/w), as seen in Figure 4 . The fact that the polymers used in the ISFI system are not water soluble in higher than 10% aqueous solutions, limited the water content in the ISFI. Although rhBMP-2 directly dissolved in acetic acid/NMP mixtures inactivated the growth factor, rhBMP-2 dissolved in an aqueous acetic acid solution and then further diluted in NMP was active. Due to system constraints, the maximum percentage of NMP that could be tested was 97.5%, but the rhBMP-2 activity in this condition was equivalent to the controls of rhBMP-2 and NMP separately added to cells in the alkaline phosphatase assay. Therefore, particular processing methods maintained the activity of BMP-2 in a highly organic solvent environment. 
solutions (gray diagonal hashed bars). Cells only and NMP served as negative controls and BMP-2 (in aqueous solution) and BMP-2 (in aqueous solution) and NMP added directly to the well served as positive controls (solid gray bars). All data is normalized to the positive control of BMP-2 (in aqueous solution). Mean ± SD (n=3).
Since the rhBMP-2 must be partially dissolved in aqueous solution to remain active, the effect of aqueous solution included in the IFSI system on the NMP release was tested using RG502, the lowest molecular weight polymer with 50 mol% lactide.
During the first 24 h, the NMP release was slightly lower when water was included, although this difference was not significant ( Figure 5 ). Over the course of 28 days, the cumulative NMP release was entirely equivalent for solvent with only NMP or with up to 10% (w/w) water. It is important to note that the concentration of NMP was different since the total amount of NMP was higher when only NMP was used as the solvent.
Thus, the addition of a small amount of water did not affect the ISFI system release characteristics. The preliminary studies showed that there was potential to include rhBMP-2 without dramatically changing the ISFI system to enable delivery of an active growth factor. Therefore, rhBMP-2 was added to the polymer and NMP in an acid solution as 10% (w/w) of the total solvent. rhBMP-2 release, measured at weekly intervals up to 28 days, indicated that there was a very low level of release initially for both RG502 (50 mol% lactide) and RG752 (75 mol% lactide) ( Figure 6 ). By 21 days, release dramatically increased, with practically all of the rhBMP from the RG502 ISFI ending up in the supernatant whereas about only half of the rhBMP in the RG752 IFSI was released. At 28 days, both polymers had released essentially all of the rhBMP. 
In Vivo Bone Formation with ISFI
The ISFI with 50% lactide (RG502) and 75% lactide (RG752) were tested in vivo in a cranial defect model in rabbits. Since the degradation characteristics of the materials would also influence the healing of the defect, a titanium based scaffold was used (Fig. 7a ) so that the ISFI could be placed in the center of the defect (Fig. 7b) . By doing so, the presence of the ISFI would not directly interfere with bone regeneration occurring predominantly from the defect margins besides the exposure to NMP, rhBMP-2 and possibly degradation products released from the ISFI. For all the animals, the healing over a 16 week time period was uneventful. The histological sections revealed that bone formation has occurred in this critical size defect model to a great extent ( Fig.   7e-g ). Defect bridging between the four groups was not significantly different (Fig. 7h) .
Without ISFI, 78 ± 35% of the defect was bridged. With NMP loaded 50% lactide ISFI defect bridging occurred to 49 ± 18%. In the presence of the NMP/rhBMP loaded 75 mol% lactide ISFI, defect bridging occurred to 70 ± 19% and with the NMP/rhBMP loaded 50 mol% lactide ISFI, the mean defect bridging amounted to 83 ± 20%.
Without ISFI, 28 ± 15% of the implant was bony regenerated. With NMP loaded 50% lactide, ISFI bony regeneration occurred to 21 ± 9%. In the presence of the NMP/rhBMP-2 loaded 75 mol% lactide ISFI (RG752), bony regeneration occurred to 29 ± 8%, and with the NMP/rhBMP-2 loaded 50 mol% lactide ISFI (RG502), the mean bony regeneration percentage was 50 ± 12% (Fig. 7k ). Bony regeneration with the NMP/rhBMP-2 loaded 50 mol% lactide ISFI (RG502) was significantly better than with NMP/rhBMP-2 loaded 75 mol% lactide ISFI (RG752) (P=0.016), than with NMP loaded 50% lactide (P=0.003), and than without ISFI (P=0.041). Therefore, for this critical size defect treated with a titanium-based scaffold, the rhBMP-2/NMP release profile of the 50 mol% lactide ISFI was significantly better suited to enhance bony regeneration than that of the 75 mol% lactide ISFI. 
Discussion
Since our laboratory's discovery of NMP's enhancing effects on BMP-2 and bone regeneration, it has been a goal to deliver this molecule in a sustained manner to take full advantage of its benefits. However, since NMP has a very low molecular weight (99.1 g/mol) and is both water and organic-soluble, it is difficult to retain in a delivery system. If the release of NMP could be extended to at least a couple of weeks, the NMP would be available in the time period when BMP is exerting its action for regenerating bone.
Here we report that the ISFI system with polyesters was successfully engineered to deliver NMP for more than two weeks, depending on the particular polymer used. The total duration of 100% release of NMP varied based on both polymer molecular weight and the ratio of the monomers. Lower molecular weight and higher lactide percentage polymers retained NMP for an overall longer time. These data correspond to other work that indicates that the nature of release profiles in the later time points is due to polymer degradation [27] . The polyesters with higher amounts of lactide exhibit slower degradation rates due to the more hydrophobic characteristic of the lactide monomer with the extra methyl group that hinders water access [28] . Liu and Venkatraman confirmed this by demonstrating that a 75 mol% lactide PLGA ISFI degrades slower than a 50 mol% lactide polymer, and had NMP release profiles that generally agreed with those found here [27] . Solorio et al. confirm similar trends in molecular weight degradation for ISFI with different initial molecular weights [29] .
In addition to extending the release of NMP to a sufficiently long time frame, ISFI formulations were found that also restricted burst to a low amount in the first 24 h by using low molecular weight and low lactide percentage polymers. The pattern of burst followed by slow release has been previously shown to be typical for ISFI systems with PLGA and NMP [30] . However, high burst levels of NMP could potentially lead to toxic elevated concentrations of NMP. The amount of NMP burst increased with higher molecular weight, which corresponds to other studies that show greater burst release of small molecule drugs with higher molecular weight polymers [31, 32] . Prior research has indicated that ISFIs that undergo fast phase separation result in a more porous morphology that accelerates initial release [16, 30, 33, 34] . A major contributing factor to the rate of phase inversion is the hydrophobicity of the polymer with a lower water affinity leading to more rapid phase transitions. Higher molecular weight polymers have been demonstrated to have lower water solubility, indicating that they are more hydrophobic [31] , which can explain the relationship between burst and molecular weight demonstrated here. The higher burst rate of polymers with higher lactide content, which agrees with literature [27] , can also be attributed to hydrophobicity. Since lactide is more hydrophobic than glycolide [28] , the higher amount of lactide will lead to polymers of lower hydrophilicity and a faster transition rate.
In order to create a more robust bone regeneration system, exogenous rhBMP-2 was integrated into the ISFI to supplement the natural BMP-2 to enable greater NMP enhancement of BMP-2's osteogenic effects for improved bone regeneration. By introducing rhBMP-2 already dissolved in an aqueous solution into NMP, the rhBMP-2 retained its activity. Analysis of the additional water in the system mandated by the inclusion of rhBMP-2 in an aqueous solution had no significant impact on the NMP release rates even though polymer solubility differences between water and the solvent are the fundamental principle of formation of ISFIs. Since PLGA remains soluble with only a small percentage of water (6-12% aqueous solution for similar polymers in NMP) [20] , only low levels of water could be included.
rhBMP-2 release from the ISFI was studied using the two most promising polymer candidates that combine a low burst with long term NMP release: the lowest molecular weight polymers with 50 and 75 mol% lactide (RG502 and RG752). rhBMP-2 release followed trends of the NMP release, although lower relative levels of BMP-2 release are seen until day 21. Overall, the ISFI retained the rhBMP-2 for an extended period of time with only a small amount released in the first two weeks.
Previous animal studies with ISFIs and rhBMP by others are limited to a pilot study in rats [19, 35] , that indicated that the system is osteoinductive and healed periodontal defects better than a collagen delivery vehicle. An optimization in terms of NMP and rhBMP release for bone regeneration has not been performed so far. Here bone regeneration was analyzed by two ISFI systems containing the same amount of rhBMP-2 and NMP, however, releasing them with different kinetics. For the application of the ISFI we used titanium scaffolds (Fig. 7a ) that can be permanently implanted and have inherent osteoconductive properties, as demonstrated in a rabbit calvarial defect model [24] . However, the primary role of the scaffold in this study is to serve as a carrier.
Since the ISFI was placed in the middle of the scaffold a physical interference with bone in-growth occurring from the defect margins was omitted (Fig. 7b) .
The results revealed that compared to the titanium scaffold without ISFI and the titanium scaffold with the ISFI system with 50% lactide without rhBMP, only the ISFI system with a 50% lactide containing polymer performed significantly better. The same amount of NMP and rhBMP-2 released with different kinetics from the 75 mol% lactide containing polymer had no positive effect on bone regeneration determined 112 days post-surgery. A possible direct effect of the slower degradation of the 75% lactide compared to the 50% lactide was minimized in our system, since the ISFIs were placed in the center of the titanium scaffold. From the literature it is known that 80% degradation of the 75 mol% lactide implant is reached at 48 days compared to 30 days for the 50 mol% lactide system [27] . The healing model used here continued until day 112 post surgery, leaving sufficient time for undisturbed healing to occur for both materials.
NMP and BMP release profiles, not degradation, are suspected to be the major contributors to differences in bone regeneration between the RG502 and RG752 experimental groups. NMP at concentrations between 1 and 5 mM enhances BMP activity two to eight times and is most efficient at low BMP concentrations [9] . RG502, the 50 mol% lactide ISFI, may provide more optimal NMP concentrations for the greatest BMP enhancement due to its almost linear NMP release from the beginning up to 100% release on day 14 ( Figure 2 ). During these 14 days, less than 20% of the BMP was released according to the in vitro experiment, but its activity might have been enhanced several fold by the released NMP. Subsequently, the remaining 80% of the BMP-2 was released between day 14 and 21 ( Figure 6 ). Overall, one can speculate that in the ISFI group of 50 mol% lactide containing polymer, the defect was exposed to a more optimal BMP activity from the beginning by low amounts of rhBMP-2 enhanced by NMP and later by higher amounts of rhBMP-2 until day 21. In the 75 mol% lactide group, both NMP and BMP release were more sustained until day 28, making it less likely that NMP or BMP threshold levels were reached so that the overall BMP activity remained inadequate to significantly stimulate bone regeneration.
Conclusion
Taken together, our present findings demonstrate the possibility to use in situ forming implants for the dual delivery of rhBMP-2 and its enhancer NMP. For the rhBMP-2 to remain active, the growth factor has to be directly dissolved in aqueous solution to replace up to 10% of the NMP content. Dependent on the polymer molecular weight and percentage of lactide of the ISFI system, release kinetics for NMP and rhBMP-2 can be tuned and sustained release over 28 days can be achieved. For bone regeneration purposes in a critical size defect in the calvarial bone of rabbits, the faster degrading and faster NMP and rhBMP-2 releasing system with 50 mol% lactide performed better in terms of bone bridging and significantly better for the amount of the bony regenerated area in the defect. Since the optimal release kinetics of NMP and rhBMP-2 might vary between applications, the ISFI systems have to be matched to the specific requirements. Mean ± SD (n=3). Histology of the middle section: e) control is scaffold only, f) scaffold with ISFI 50% mol% lactide without BMP, g) scaffold with ISFI 75 mol% lactide with BMP, h) scaffold with ISFI 50 mol% lactide with BMP, scale in mm is provided in e; bone appears blue with Toluidine-blue staining, titanium black. i) Box-plot for defect bridging and k) bony regenerated area. * indicates P values<0.05. Exact P values are provided in the result section. Mean ± SD (n=6).
